U.S. Markets closed

Why Gilead could pay more than $2 billion in deal with this small S.F. biotech

Ron Leuty
Why Gilead could pay more than $2 billion in deal with this small S.F. biotech

Founded by three professors from UC Berkeley and UCSF, Nurix's protein-degradation approach to cancer, and potentially other diseases, could stop cancer in its tracks.